Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 3/20 | 0.41 |
| ▸ | CCND3 | P30281 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251586 | 0.85 | KDM4E (0.49) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL29493254 | 0.83 | MAPT (0.49) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL28943557 | 0.83 | MAPT (0.49) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL27306266 | 0.83 | MAPT (0.45) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL30922297 | 0.83 | CHKA (0.51) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL21414319 | 0.82 | MAPT (0.44) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL27788009 | 0.78 | CHEK1 (0.45) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL1321991 | 0.77 | AKR1C3 (0.54) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL23916695 | 0.77 | HRH3 (0.42) | MAPTHTR3AGAAKMT2AMEN1 | |
| SCHEMBL82236 | 0.75 | MAPT (0.50) | MAPTHTR3AGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284275-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-20130165449-A1 | Compounds and Method for Treatment of Cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165449-A1 | Compounds and Method for Treatment of Cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8420643-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-29 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165449-A1 | Compounds and Method for Treatment of Cancer | TBCA, SLC6A6, SLC5A1 | MAPT 39/4885HTR3A 1634/4885GAA 1943/4885 |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | SLC6A6, SLCO1B3, SLC5A1 | MAPT 30/4885HTR3A 1661/4885GAA 2363/4885 |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | TBCA, SLC6A6, SLC5A1 | MAPT 39/4885HTR3A 1634/4885GAA 1943/4885 |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | TBCA, SLC6A6, SLC5A1 | MAPT 39/4885HTR3A 1634/4885GAA 1943/4885 |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | MAPT 3309/4885HTR3A 4550/4885GAA 3414/4885 |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | MAPT 3309/4885HTR3A 4550/4885GAA 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.